[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 38,709,480
  • Shares Outstanding, K 212,596
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,131 M
  • EBIT $ -1,387 M
  • EBITDA $ -1,398 M
  • 60-Month Beta 1.40
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 25.25

Options Overview Details

View History
  • Implied Volatility 51.59% (+1.02%)
  • Historical Volatility 43.63%
  • IV Percentile 42%
  • IV Rank 15.36%
  • IV High 129.42% on 04/10/26
  • IV Low 37.46% on 09/18/25
  • Expected Move (DTE 20) 16.18 (8.89%)
  • Put/Call Vol Ratio 0.89
  • Today's Volume 2,881
  • Volume Avg (30-Day) 5,515
  • Put/Call OI Ratio 0.56
  • Today's Open Interest 62,366
  • Open Int (30-Day) 109,667
  • Expected Range 165.90 to 198.26

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.90
  • Number of Estimates 9
  • High Estimate $-0.85
  • Low Estimate $-2.19
  • Prior Year $-1.31
  • Growth Rate Est. (year over year) -45.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
141.44 +28.73%
on 06/10/26
184.39 -1.25%
on 06/25/26
+27.19 (+17.55%)
since 05/26/26
3-Month
91.52 +98.95%
on 03/30/26
184.39 -1.25%
on 06/25/26
+88.87 (+95.34%)
since 03/26/26
52-Week
34.00 +435.53%
on 08/07/25
184.39 -1.25%
on 06/25/26
+144.60 (+385.81%)
since 06/26/25

Most Recent Stories

More News
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 182.08 (+2.19%)
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer 

REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 182.08 (+2.19%)
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy...

RVMD : 182.08 (+2.19%)
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer

REDWOOD CITY, Calif., May 31, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,...

RVMD : 182.08 (+2.19%)
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,...

RVMD : 182.08 (+2.19%)
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer

REDWOOD CITY, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 182.08 (+2.19%)
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress

Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary presentation...

RVMD : 182.08 (+2.19%)
Revolution Medicines: The Daraxonrasib Enthusiasm Before Any Commercial Reality Check

Barchart Research What to Expect from RVMD Earnings RVMD Generated May 5, 2026 Current Price $147.21 EPS Estimate $$-1.83 Consensus Rating Strong Buy Average Move 3.43% Revolution Medicines: The Daraxonrasib...

RVMD : 182.08 (+2.19%)
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 182.08 (+2.19%)
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 182.08 (+2.19%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 194.64
2nd Resistance Point 189.00
1st Resistance Point 185.54
Last Price 182.08
1st Support Level 176.44
2nd Support Level 170.80
3rd Support Level 167.34

See More

52-Week High 184.39
Last Price 182.08
Fibonacci 61.8% 126.94
Fibonacci 50% 109.19
Fibonacci 38.2% 91.45
52-Week Low 34.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.